I have spent my entire academic career as a clinical investigator and have grown to recognize the importance of a strong and vibrant rheumatology workforce. However, I am deeply concerned about our ability as a subspecialty to sustain our research enterprise and take advantage of the modern breakthroughs in science. The reduction in federal funding…
There can be a rhythm to rheumatology. At least that’s what Alain Alvarez, MD, can sometimes find. Listening, assessing, helping. It can be a successful dance when doctor and patient become partners, hoping to lead each other forward. When you consider this, it might be little surprise that Dr. Alvarez is also a dance teacher….
Arthritis Center Renamed to Honor Ephraim P. Engleman, MD Ephraim P. Engleman, MD, has been on the faculty at the University of California, San Francisco (UCSF) since 1947, 10 years after he received his MD from Columbia University. The 104-year-old rheumatologist is currently the director of the Rosalind Russell/Ephraim P. Engleman Rheumatology Research Center, which…
CHICAGO—With the approval of the Jak inhibitors (i.e., jakinibs) tofacitinib and ruxolitinib—and others being investigated—rheumatologists need to arm themselves with an understanding of these drugs so they can think critically when evaluating them and deciding how to use them, said John O’Shea, MD, chief of the Molecular Immunology and Inflammation Branch of and scientific director…
CHICAGO—Stem cell transplantation for systemic sclerosis patients has come a long way over the past decade, with more finely calibrated dosing and better patient selection, said George Georges, MD, associate member of the Fred Hutchinson Cancer Research Center and associate professor in the medical oncology division at the University of Washington School of Medicine, Seattle,…
CHICAGO—Scleroderma patients with pulmonary arterial hypertension (PAH) might benefit from more aggressive therapy, an expert in the field said in a session on lung involvement in rheumatic diseases at the American College of Rheumatology’s 2015 State-of-the-Art Clinical Symposium in May. Newer trials—the SERAPHIN trial on macitentan, GRIPHON on selexipag, and AMBITION on an ambrisentan/tadalafil combination—show…
In terms of getting our message heard in Washington, D.C., rheumatology faces a David vs. Goliath battle on several levels. Many industries have far greater resources, use multiple lobbying firms, and have advertising and lobbying budgets that eclipse ours by several hundred-fold. Rheumatology is far smaller than most other medical specialties; our membership is a…
The annual ACR State-of-the-Art (SOTA) Clinical Symposium came highly endorsed by previous fellows; therefore, upon receiving the invitation for the Fellows-in-Training (FIT) scholarship, I did not hesitate to apply. Further, the meeting was going to be held in the spring in Chi Town! Meticulously, I made arrangements with six hundred scholarship dollars at my disposal….
On July 1, 2015, the Rheumatology Research Foundation awarded more than 80 grants to a wide range of rheumatology trainees and professionals. The recipients, who submitted applications in 2014, will receive funding for essential education and training, as well as innovative research projects. Their applications were closely examined by experts in different areas of the…
ATLANTA, Ga.—The American College of Rheumatology (ACR) today praised the Centers for Medicare and Medicaid Services (CMS) for issuing new guidance to provide a 12-month “safe harbor” period for physicians following the Oct. 1 implementation of the ICD-10 code set. The ACR has led legislative and grassroots efforts to responsibly address the transition to the…